BALTIMORE, July 9, 2020 /PRNewswire-PRWeb/
-- PathSensors Inc., a Baltimore biotechnology company, announced
today that Massachusetts Institute of
Technology (MIT) has expanded
the company's exclusive license to include clinical applications
for CANARY™ technology. This broader license allows PathSensors to
move into the point-of-care diagnostic market, focusing initially
on the SARS-CoV-2 biosensor. CANARY's™ fast and highly sensitive
assays will help to address the shortage of COVID-19 testing
capabilities in the United
States.
The company's core business is environmental testing in fields
such as building protection, mail security, food safety, and
agriculture. Test panels for other infectious diseases will follow
in future years.
"PathSensors originally developed CANARY™ technology for
commercial use in 2012," stated PathSensors' President,
Ted Olsen. "Now 8 years later, we
are bringing CANARY™ to the healthcare field to provide rapid and
highly sensitive detection solutions for a major public health
crisis."
About CANARY™
CANARY™ is a biosensor technology that delivers extremely rapid
detection of pathogens with high sensitivity and specificity.
Originally developed by scientists at MIT–Lincoln Laboratory to
combat bioterrorism threats, CANARY™ has been licensed and
commercialized by PathSensors, Inc.
About PathSensors, Inc.
PathSensors is a leading environmental testing company offering
cutting-edge pathogen detection capabilities to a variety of
industries including food safety, agriculture, infectious disease,
and bioterrorism. The company makes the world a safer place by
detecting pathogens that can cause sickness or worse while creating
high technology jobs in the state of Maryland.
SOURCE PathSensors Inc.